Account
Inquiry
Tirzepatide 10mg (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This innovative peptide demonstrates superior efficacy in glucose control and weight management compared to single receptor agonists.
As a research compound, tirzepatide 10mg offers unique dual mechanism of action with greater affinity for GIP receptors than GLP-1 receptors. Clinical studies have shown this dual agonist behavior produces more significant reductions in hyperglycemia compared to selective GLP-1 receptor agonists alone.
The molecular structure of tirzepatide 10mg features PEG modification on the lysine side chain, enhancing water solubility while maintaining biological activity. This modification contributes to the peptide's extended half-life and sustained pharmacological effects.
In clinical trials, tirzepatide 10mg demonstrated remarkable weight loss results. The SURMOUNT-1 study reported average weight reductions of 19.5% with the 10mg dose after 72 weeks of administration. These findings highlight the compound's potential for metabolic disorder research.
Our tirzepatide 10mg is supplied as a lyophilized powder with guaranteed 99% purity, meeting strict pharmaceutical grade standards. Each batch undergoes comprehensive quality control testing including HPLC and mass spectrometry analysis to ensure consistency and reliability for research applications.
Note: This product is intended for research purposes only. Not for human consumption or diagnostic use. Researchers should handle all peptides following appropriate laboratory safety protocols.
